On November 17, 2025 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Candel’s R&D Day will include presentations and panel discussions from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline. Click here to register for the event.
The R&D Day will include the following presentations:
Introduction to Candel Therapeutics:
Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and CEO
Panel Discussion: Immuno-oncology: The next wave of innovation
Panelists:
James P. Allison, PhD, Nobel Laureate, Regental Professor and Chair of Immunology, and Founding Director of Scientific Programs for the James P. Allison Institute at the University of Texas MD Anderson Cancer Center
Carl H. June, MD, Richard W. Vague Professor in Immunotherapy and Director, Center for Cellular Immunotherapies and Parker Institute for Cancer Therapy, Perelman School of Medicine, University of Pennsylvania
Padmanee Sharma, MD, PhD, Professor of Genitourinary Medical Oncology and Immunology, and Director of Scientific Programs for the James P. Allison Institute at the University of Texas MD Anderson Cancer Center
Moderator: Yigal Nochomovitz, PhD, Citi Group
CAN-2409 for newly diagnosed localized prostate cancer
Glen Gejerman, MD, Co-chief of Urologic Oncology, Hackensack University Medical Center
Philip Kantoff, MD, Former Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center, CEO, Convergent Therapeutics
Garrett Nichols, MD, MS, Candel’s Chief Medical Officer
Ron Tutrone, MD, National Director of Clinical Research, United Urology
Moderator: Oliver McCammon, LifeSci Capital
CAN2409: Roadmap to Biologics License Application (BLA)
Sue Stewart, JD, Candel’s Chief Regulatory Officer
Seshu Tyagarajan, PhD, Candel’s Chief Technical and Development Officer
Moderator: Andres Maldonado, PhD, HC Wainwright & Co.
CAN-2409: Pre-commercialization roadmap
Jonathan Mitchell, MSc, Partner, Globe Life Sciences
Jacqueline Poot, President, IDEA Pharma
Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and CEO
Moderator: Andres Maldonado, PhD, HC Wainwright & Co.
CAN-2409 for immune checkpoint inhibitor refractory non-small cell lung cancer
Panelists:
Charu Aggarwal, MD, Professor of Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Yale Cancer Center
Dan Sterman, MD, Thomas and Suzanne Murphy Professor of Medicine and Cardiothoracic Surgery, NYU Langone Health
Moderator: John Newman, PhD, Canaccord Genuity
CAN-3110 for recurrent glioblastoma
Francesca Barone, MD, PhD, Candel’s Chief Scientific Officer
Henry Brem, MD, Professor of Neurosurgery, Johns Hopkins University
Moderator: Kemp Dolliver, Brookline Capital Markets
Registration for this virtual event and access to the live webcast and subsequent replay will be accessible under "Events and Presentations" on the Investors page of the Company’s website at www.candeltx.com or by clicking here.
About CAN-2409
CAN-2409 (aglatimagene besadenovec), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 in clinical trials with a favorable tolerability profile to date, supporting the potential for combination with standard of care, when indicated.
About CAN-3110
CAN-3110 (linoserpaturev) is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) next-generation oncolytic viral immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. In October 2023, the Company announced that Nature published results from the ongoing clinical trial where CAN-3110 was reported to be generally well tolerated with no dose-limiting toxicity. In the clinical trial, the investigators observed improved mOS compared to historical controls after a single CAN-3110 injection in this therapy-resistant condition.1 The Company and academic collaborators are currently supported by the Break Through Cancer foundation.
(Press release, Candel Therapeutics, NOV 17, 2025, View Source [SID1234660033])